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  The basic fetoprotein in the serum of patients with urogenital tract diseases was measured using
radioimmunoassay， and the following results were obtained． Serum BFP values were divided into
three groups： Negative， false positive and positive for va1ues below I OO ngfml， 100一一129 ng／ml and
above 130 ng／rnl， respectively． The BFP positive rate for the benign diseases was 21．2 O／o and par－
ticularly high in the cases of acute infiammation． The BFP positive rate for the patients with urogenital
malignant tumors， was 46．80／，． After radical therapy it was 9．50／．． Serum BFP， fi－HCG and AFP
values were measured in the 81 cases of testicular tumor． The BFP positive rate was 55．0 O／o and the
β一HCG positive rate was 40％fbr the 20 cases ofseminoma． The BFP posit三ve rate fbr l l non－seminoma
cases was 27．30／o， the P一｝ICG positive rate was 36．40／， and the AFP （8 cases） positive rate was 62．5 O／，．
  1£ we regarded the case positive when at least one’ of the parameters， BFP， P－HCG or AFP was
positive， 65．00／， of the 20 cases of serpinoma and 55．60／o of the 11 non－seminoma cases were positive．
  It was concluded that the measurement of BFP is significantly eMcient as a tumor marker for
urogenital tumor； particularly for testicular tumors， the measurement of P－HCG， AFP and BFP in
combination very usefu1．
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せることにより，その目的に近づくことを考え泌尿生
殖器系悪性腫瘍を対象として，従来よりα一fetoprotein
（以下AFP）， human chorionic gonadotropin（以下
HCG）， carcinoembryonic antigen（CEA）および
































田  ＠ iP51－BFP： O． l ml（10，000CPM）
； lncubation 48hr 4eC
第2抗体：0，1ml
l lncubation 12－24hr 4”C
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20例embryonal carcinoma 4例， teratocarcinoma 1
例，rhabdomyosarcoma 1例， choriocarcinoma 1例，
混合腫瘍4例である．
 clinical stageと血清BFP値の関係はTable 5の










T∂ble 4 睾ブL月重瘍  （1） 睾丸腫瘍（2）
  BFP B－HCG AFP症（ng！磁）（ng！mの（ngfme）
例 前   前   前
後 後 後
B   Stage  組 織儲索血）
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     （除睾術前31例）（％）
Seminoma Non－Seminoma
 BFP 11／20 （55．0）
B－HCG 8／20 （40．0）
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